{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T18:34:17Z","timestamp":1775586857185,"version":"3.50.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009129","name":"Evidence Synthesis Programme","doi-asserted-by":"publisher","award":["NIHR153779"],"award-info":[{"award-number":["NIHR153779"]}],"id":[{"id":"10.13039\/501100009129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Late-onset Pompe disease (LOPD) is a rare inherited genetic condition caused by deficiency of acid \u03b1-glucosidase (GAA) and accumulation of lysosomal glycogen. LOPD causes progressive muscle dysfunction and damage, leading to significant morbidity and early mortality. Enzyme replacement therapy (ERT) is the primary treatment for Pompe disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A systematic review and network meta-analysis of published evidence on the clinical effectiveness of ERT and best supportive care (BSC) was undertaken to establish the relative effectiveness of ERT compared to BSC (in the absence of ERT). Bibliographic databases were searched to identify randomised controlled trials (RCTs) or any other prospective ERT studies in patients with Pompe disease. Network meta-analyses (NMA) of RCTs were undertaken to estimate indirect treatment effects for forced vital capacity (FVC) % predicted and the 6-minute walk test (6MWD). A narrative synthesis was employed to summarise other studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 38 studies were included in the review. They comprised three RCTs, three RCT extension studies, seven registry studies and 25 single-group prospective studies. The results of two RCTs were judged to have a high risk of bias. In the NMA, after approximately one year, ERT-na\u00efve patients showed significant 6MWD improvements vs. placebo: ~25\u00a0m with alglucosidase alfa and ~\u200954\u00a0m with avalglucosidase alfa. No significant differences were found for FVC % predicted or comparisons with cipaglucosidase alfa, although very few ERT-na\u00efve patients taking cipaglucosidase alfa were available for the analyses. Intra-ERT comparisons showed a significant 6MWD advantage for avalglucosidase alfa. However, a sensitivity analysis adjusting for skewed data revealed no significant differences. Long-term ERT effectiveness was assessed in single-group studies, showing initial gains maintained for 1\u20133 years, followed by gradual 10\u201315-year declines in 6MWD and FVC % predicted. However, small sample sizes and missing data introduce uncertainty.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our NMA results showed that ERTs lead to modest improvements in 6MWD after 1 year compared to placebo in ERT-naive populations. However, there is limited evidence supporting meaningful differences in outcomes between ERTs. There is a lack of longer-term follow-up data supporting the effectiveness of ERTs compared to each other and to best supportive care.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03981-0","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T18:17:44Z","timestamp":1755800264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Enzyme replacement therapy for the treatment of late onset Pompe disease: A systematic review and network meta-analysis"],"prefix":"10.1186","volume":"20","author":[{"given":"Mark","family":"Corbett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinyereugo","family":"Umemneku-Chikere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Nevitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nyanar Jasmine","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Walton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Fulbright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong Yew","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Churchill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6962-2893","authenticated-orcid":false,"given":"Robert","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"3981_CR1","unstructured":"National Institutes of Health. Pompe disease. NIH; n.d. [13 December 2023)]; Available from: https:\/\/www.ninds.nih.gov\/health-information\/disorders\/pompe-disease"},{"key":"3981_CR2","doi-asserted-by":"crossref","unstructured":"n der Ploeg A, Carlier PG, Carlier RY, Kissel JT, Schoser B, Wenninger S et al. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study. Molecular Genetics & Metabolism. [Clinical Trial, Phase IV Multicenter Study Research Support, Non-U.S. Gov\u2019t]. 2016 09;119(1\u20132):115\u2009\u2013\u200923.","DOI":"10.1016\/j.ymgme.2016.05.013"},{"key":"3981_CR3","doi-asserted-by":"crossref","unstructured":"n der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ et al. A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N Engl J Med. [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov\u2019t]. 2010;362(15):1396\u2009\u2013\u2009406.","DOI":"10.1056\/NEJMoa0909859"},{"issue":"9646","key":"3981_CR4","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT n der Ploeg","year":"2008","unstructured":"n der Ploeg AT, Reuser AJ. Pompe\u2019s disease. Lancet [Review]. 2008;372(9646):1342\u201353.","journal-title":"Lancet [Review]"},{"key":"3981_CR5","doi-asserted-by":"crossref","unstructured":"n der Ploeg AT, Kruijshaar ME, Toscano A, Laforet P, Angelini C, Lachmann RH et al. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol. [Review Systematic Review]. 2017 06;24(6):768-e31.","DOI":"10.1111\/ene.13285"},{"key":"3981_CR6","doi-asserted-by":"crossref","unstructured":"Gungor D, Kruijshaar ME, Plug I, Rizopoulos D, Kanters TA, Wens SC et al. Quality of life and participation in daily life of adults with Pompe disease receiving enzyme replacement therapy: 10 years of international follow-up. J Inherit Metab Dis. [Observational Study Research Support, Non-U.S. Gov\u2019t]. 2016;39(2):253\u2009\u2013\u200960.","DOI":"10.1007\/s10545-015-9889-6"},{"issue":"21","key":"3981_CR7","first-page":"21","volume":"10","author":"AD Dornelles","year":"2021","unstructured":"Dornelles AD, Junges APP, Pereira TV, Krug BC, Goncalves CBT, Llerena JC Jr., et al. A systematic review and Meta-Analysis of enzyme replacement therapy in Late-Onset Pompe disease. J Clin Med [Review]. 2021;10(21):21.","journal-title":"J Clin Med [Review]"},{"key":"3981_CR8","first-page":"1","volume":"05","author":"J Milverton","year":"2018","unstructured":"Milverton J, Newton S, Merlin T. The effectiveness of enzyme replacement therapy for juvenile-onset Pompe disease: a systematic review. J Inherit Metab Dis [In Press]. 2018;05:1\u20138.","journal-title":"J Inherit Metab Dis [In Press]"},{"key":"3981_CR9","doi-asserted-by":"crossref","unstructured":"Junges APP, Dornelles AD, da Veiga Pereira T, Krug B, Goncalves C, Schwartz IVD. A meta-analysis of enzyme replacement therapy in late-onset Pompe disease. Mol Genet Metab. [Conference Abstract]. 2021 February;132(2):S84.","DOI":"10.1016\/j.ymgme.2020.12.199"},{"key":"3981_CR10","unstructured":"National Institute for H, Care E. Avalglucosidase Alfa for treating Pompe disease. NICE technology appraisal guidance 821. England: National Institute for Health and Care Excellence (NICE)2022."},{"key":"3981_CR11","volume-title":"Cipaglucosidase Alfa with miglustat for treating late-onset Pompe disease. NICE technology appraisal guidance 912","author":"E Care","year":"2023","unstructured":"National Institute for H, Care E. Cipaglucosidase Alfa with miglustat for treating late-onset Pompe disease. NICE technology appraisal guidance 912. England: National Institute for Health and Care Excellence (NICE); 2023."},{"issue":"10","key":"3981_CR12","doi-asserted-by":"publisher","first-page":"e240045","DOI":"10.57264\/cer-2024-0045","volume":"13","author":"S Shohet","year":"2024","unstructured":"Shohet S, Hummel N, Fu S, Keyzor I, MacCulloch A, Johnson N, et al. Comparing the efficacy of cipaglucosidase Alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data. J Comp Eff Res. 2024;13(10):e240045.","journal-title":"J Comp Eff Res"},{"key":"3981_CR13","unstructured":"Deegan P. Guidelines for the investigation and management of late onset acid maltase deficiency (type ii glycogen storage disease \/ pompe disease). Version 3. 2007."},{"key":"3981_CR14","unstructured":"Department of Health. National Specialist Commissioning Advisory Group annual report 2006\/07. London: Department of Health2007."},{"key":"3981_CR15","volume-title":"National designation and funding of the service for patients with lysosomal storage","author":"J Stallibrass","year":"2004","unstructured":"Stallibrass J, Letter. National designation and funding of the service for patients with lysosomal storage. disorders London: Department of Health; 2004."},{"key":"3981_CR16","unstructured":"Sanofi Genzyme M. 2021 [December 2024]]; Available from: https:\/\/www.medicines.org.uk\/emc\/product\/263\/smpc"},{"key":"3981_CR17","volume-title":"Systematic reviews: crd\u2019s guidance for undertaking reviews in healthcare","author":"Centre for Reviews and Dissemination","year":"2009","unstructured":"Centre for Reviews and Dissemination. Systematic reviews: crd\u2019s guidance for undertaking reviews in healthcare. York: CRD, University of York; 2009."},{"key":"3981_CR18","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372.","DOI":"10.1136\/bmj.n71"},{"key":"3981_CR19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"3981_CR20","unstructured":"Food and Drug Administration. Integrated Review: Nexviazyme (avalglucosidase alfa-ngpt). Silver Spring, MA: FDA2020."},{"key":"3981_CR21","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. 2023 [cited 2025 14 February]; Available from: https:\/\/www.R-project.org\/"},{"key":"3981_CR22","unstructured":"Plummer M, Stukalov A, Denwood M. Package \u2018rjags\u2019: Bayesian graphical models using MCMC. CRAN; 2024 [cited 2025 14 February]; Available from: https:\/\/cran.r-project.org\/web\/packages\/rjags\/rjags.pdf"},{"key":"3981_CR23","volume-title":"NICE DSU technical support document 2: A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials","author":"S Dias","year":"2014","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU technical support document 2: A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. Sheffield: Decision Support Unit, ScHARR, University of Sheffield; 2014."},{"key":"3981_CR24","unstructured":"Schoser B, Roberts M, Byrne BJ, Sitaraman S, Jiang H, Laforet P et al. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurology. [Clinical Trial, Phase III Randomized Controlled Trial Research Support, Non-U.S. Gov\u2019t]. 2021 12;20(12):1027-37."},{"key":"3981_CR25","unstructured":"Diaz-Manera J, Kishnani PS, Kushlaf H, Ladha S, Mozaffar T, Straub V et al. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial. Lancet Neurology. [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov\u2019t]. 2021 12;20(12):1012-26."},{"key":"3981_CR26","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1007\/s00415-024-12236-0","volume":"271","author":"B Schoser","year":"2024","unstructured":"Schoser B, Kishnani PS, Bratkovic D, Byrne BJ, Claeys KG, Diaz-Manera J, et al. 104-week efficacy and safety of cipaglucosidase Alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07). J Neurol. 2024;271:2810\u201323.","journal-title":"J Neurol"},{"key":"3981_CR27","doi-asserted-by":"crossref","unstructured":"n der Ploeg AT, Barohn R, Carlson L, Charrow J, Clemens PR, Hopkin RJ et al. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. Molecular Genetics & Metabolism. [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov\u2019t]. 2012;107(3):456\u2009\u2013\u200961.","DOI":"10.1016\/j.ymgme.2012.09.015"},{"key":"3981_CR28","unstructured":"Kishnani PS, Diaz-Manera J, Toscano A, Clemens PR, Ladha S, Berger KI et al. Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial. JAMA Neurology. [Randomized Controlled Trial Clinical Trial, Phase III Research Support, Non-U.S. Gov\u2019t]. 2023 06 01;80(6):558\u201367."},{"key":"3981_CR29","doi-asserted-by":"crossref","unstructured":"Berger KI, Chien Y-H, Dubrovsky A, Kishnani PS, Llerena JC, Neilan E et al. Changes in forced vital capacity over \u2264 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe registry. J Neurol. 2024.","DOI":"10.1007\/s00415-025-13147-4"},{"issue":"10","key":"3981_CR30","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1007\/s00415-020-09936-8","volume":"267","author":"DW Stockton","year":"2020","unstructured":"Stockton DW, van der Kishnani P, Llerena J Jr., Boentert M, Roberts M, et al. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start. J Neurol. 2020;267(10):3038\u201353.","journal-title":"J Neurol"},{"key":"3981_CR31","doi-asserted-by":"crossref","unstructured":"Marcondes B, Wilker E, Laredo F, Llerena J, Falavigna M. PRO6 Characteristics of Late Onset Pompe Disease Patients in Latin America - a Patient Registry Analysis. Value Health. [Conference Abstract]. 2020 December;23(Supplement 2):S690-S1.","DOI":"10.1016\/j.jval.2020.08.1742"},{"key":"3981_CR32","doi-asserted-by":"crossref","unstructured":"Semplicini C, De Antonio M, Taouagh N, Behin A, Bouhour F, Echaniz-Laguna A et al. Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry. J Inherit Metab Dis. [Multicenter Study Observational Study Research Support, Non-U.S. Gov\u2019t]. 2020 11;43(6):1219-31.","DOI":"10.1002\/jimd.12272"},{"key":"3981_CR33","unstructured":"Lefeuvre C, De Antonio M, Bouhour F, Tard C, Salort-Campana E, Lagrange E et al. Characteristics of patients with Late-Onset Pompe disease in france: insights from the French Pompe registry in 2022. Neurology. [Research Support, Non-U.S. Gov\u2019t]. 2023 08 29;101(9):e966\u201377."},{"key":"3981_CR34","doi-asserted-by":"crossref","unstructured":"Tard C, Bouhour F, Michaud M, Beltran S, Fournier M, Demurger F et al. Real-life effectiveness 1 year after switching to avalglucosidase Alfa in late-onset Pompe disease patients worsening on alglucosidase Alfa therapy: A French cohort study. Eur J Neurol. 2024:e16292.","DOI":"10.1111\/ene.16292"},{"key":"3981_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nmd.2023.10.001","volume":"34","author":"RJ Martinez-Marin","year":"2024","unstructured":"Martinez-Marin RJ, Reyes-Leiva D, Nascimento A, Muelas N, Dominguez-Gonzalez C, Paradas C, et al. Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry. Neuromuscul Disord. 2024;34:1\u20138.","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"3981_CR36","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s10545-014-9728-1","volume":"37","author":"LJ Anderson","year":"2014","unstructured":"Anderson LJ, Henley W, Wyatt KM, Nikolaou V, Waldek S, Hughes DA, et al. Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study. J Inherit Metab Dis. 2014;37(6):945\u201352. Multicenter Study Observational Study Research Support, Non-U.S. Gov\u2019t.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"3981_CR37","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s00415-011-6293-5","volume":"259","author":"C Angelini","year":"2012","unstructured":"Angelini C, Semplicini C, Ravaglia S, Bembi B, Servidei S, Pegoraro E, et al. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol [Multicenter Study]. 2012;259(5):952\u20138.","journal-title":"J Neurol [Multicenter Study]"},{"key":"3981_CR38","doi-asserted-by":"crossref","unstructured":"Angelini C, Semplicini C, Ravaglia S, Moggio M, Comi GP, Musumeci O et al. New motor outcome function measures in evaluation of late-onset Pompe disease before and after enzyme replacement therapy. Muscle & Nerve. [Research Support, Non-U.S. Gov\u2019t]. 2012;45(6):831-4.","DOI":"10.1002\/mus.23340"},{"key":"3981_CR39","doi-asserted-by":"crossref","unstructured":"Bembi B, Pisa FE, Confalonieri M, Ciana G, Fiumara A, Parini R et al. Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. J Inherit Metab Dis. [Clinical Trial Multicenter Study Research Support, Non-U.S. Gov\u2019t]. 2010;33(6):727\u2009\u2013\u200935.","DOI":"10.1007\/s10545-010-9201-8"},{"issue":"20113","key":"3981_CR40","first-page":"20","volume":"01","author":"KG Claeys","year":"2022","unstructured":"Claeys KG, D\u2019Hondt A, Fache L, Peers K, Depuydt CE. Six-Minute walk distance is a useful outcome measure to detect motor decline in treated Late-Onset Pompe disease patients. Cells. 2022;01(20113):20.","journal-title":"Cells"},{"key":"3981_CR41","doi-asserted-by":"crossref","unstructured":"Clemens P, Laforet P, Kacena K, Sanson BJ, Hopkin R, Van DPA. Long-term efficacy of alglucosidase alfa in late-onset pompe disease. Neurology. [Journal article; Conference proceeding]. 2017;88(16).","DOI":"10.1212\/WNL.88.16_supplement.P1.120"},{"key":"3981_CR42","doi-asserted-by":"crossref","unstructured":"de Vries JM, van der Beek NA, Hop WC, Karstens FP, Wokke JH, de Visser M, et al. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis. 2012;7:73. [Research Support, Non-U.S. Gov\u2019t].","DOI":"10.1186\/1750-1172-7-73"},{"issue":"5","key":"3981_CR43","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s40259-023-00609-2","volume":"37","author":"IAM Ditters","year":"2023","unstructured":"Ditters IAM, van Kooten HA, Hardon JF, Ismailova G, Brusse E, et al. Home-Based infusion of alglucosidase Alfa can safely be implemented in adults with Late-Onset Pompe disease: lessons learned from 18,380 infusions. Biodrugs. 2023;37(5):685\u201398.","journal-title":"Biodrugs"},{"key":"3981_CR44","doi-asserted-by":"crossref","unstructured":"Gungor D, Kruijshaar ME, Plug I, D\u2019Agostino RB, Hagemans ML, van Doorn PA et al. Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet Journal Of Rare Diseases. [Research Support, Non-U.S. Gov\u2019t]. 2013;8:49.","DOI":"10.1186\/1750-1172-8-49"},{"key":"3981_CR45","doi-asserted-by":"crossref","unstructured":"Hahn SH, Kronn D, Leslie ND, Pena LDM, Tanpaiboon P, Gambello MJ et al. Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4,000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study. Genetics in Medicine. [Clinical Trial, Phase IV Research Support, Non-U.S. Gov\u2019t]. 2018 10;20(10):1284-94.","DOI":"10.1038\/gim.2018.2"},{"key":"3981_CR46","doi-asserted-by":"crossref","unstructured":"Harlaar L, Hogrel JY, Perniconi B, Kruijshaar ME, Rizopoulos D, Taouagh N et al. Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease. Neurology. [Research Support, Non-U.S. Gov\u2019t]. 2019 11 05;93(19):e1756-e67.","DOI":"10.1212\/WNL.0000000000008441"},{"key":"3981_CR47","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1016\/S0149-2918(07)80460-7","volume":"29","author":"R Hartung","year":"2007","unstructured":"Hartung R, Chamsi-Bacha F, Beck PDM, Mengel DmE. Initial therapy response of 6 months of enzyme replacement therapy in 11 juvenile\/adult M. Pompe patients. Clin Ther. 2007;29:S86\u20137. SUPPL. C).","journal-title":"Clin Ther"},{"issue":"23","key":"3981_CR48","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","volume":"89","author":"E Kuperus","year":"2017","unstructured":"Kuperus E, Kruijshaar ME, Wens SCA, de Vries JM, van der Favejee MM, et al. Long-term benefit of enzyme replacement therapy in Pompe disease: A 5-year prospective study. Neurology. 2017;89(23):2365\u201373.","journal-title":"Neurology"},{"issue":"12","key":"3981_CR49","doi-asserted-by":"publisher","first-page":"e0208854","DOI":"10.1371\/journal.pone.0208854","volume":"13","author":"E Kuperus","year":"2018","unstructured":"Kuperus E, van der Meijden JC, In \u2018t Groen SLM, Kroos MA, Hoogeveen-Westerveld M, Rizopoulos D, et al. The ACE I\/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease. PLoS ONE. 2018;13(12):e0208854. Clinical Trial Research Support, Non-U.S. Gov\u2019t.","journal-title":"PLoS ONE"},{"key":"3981_CR50","doi-asserted-by":"publisher","first-page":"793566","DOI":"10.3389\/fcell.2022.793566","volume":"10","author":"S Ravaglia","year":"2022","unstructured":"Ravaglia S, de Giuseppe R, Carlucci A, Jehne S, Crescimanno G, Ahmad L, et al. Bioimpedance phase angle as a prognostic tool in Late-Onset Pompe disease: A Single-Centre prospective study with a 15-year Follow-Up. Front Cell Dev Biology. 2022;10:793566.","journal-title":"Front Cell Dev Biology"},{"key":"3981_CR51","doi-asserted-by":"crossref","unstructured":"Ravaglia S, De Filippi P, Pichiecchio A, Ponzio M, Saeidi Garaghani K, Poloni GU et al. Can genes influencing muscle function affect the therapeutic response to enzyme replacement therapy (ERT) in late-onset type II glycogenosis? Molecular Genetics & Metabolism. [Clinical Trial Research Support, Non-U.S. Gov\u2019t]. 2012;107(1\u20132):104\u2009\u2013\u200910.","DOI":"10.1016\/j.ymgme.2012.05.016"},{"key":"3981_CR52","doi-asserted-by":"crossref","unstructured":"Regnery C, Kornblum C, Hanisch F, Vielhaber S, Strigl-Pill N, Grunert B, et al. 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase Alfa enzyme replacement therapy. J Inherit Metab Dis. 2012;35(5):837\u201345. Clinical Trial Research Support, Non-U.S. Gov\u2019t.","DOI":"10.1007\/s10545-012-9451-8"},{"issue":"1","key":"3981_CR53","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","volume":"257","author":"S Strothotte","year":"2010","unstructured":"Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C, et al. Enzyme replacement therapy with alglucosidase Alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol [Clinical Trial]. 2010;257(1):91\u20137.","journal-title":"J Neurol [Clinical Trial]"},{"key":"3981_CR54","doi-asserted-by":"crossref","unstructured":"n der Meijden JC, Kruijshaar ME, Rizopoulos D, van Doorn PA. Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients. Orphanet Journal Of Rare Diseases. [Research Support, Non-U.S. Gov\u2019t]. 2018 05 22;13(1):82.","DOI":"10.1186\/s13023-018-0824-4"},{"key":"3981_CR55","doi-asserted-by":"crossref","unstructured":"n der Meijden JC, Kruijshaar ME, Harlaar L, van der Rizopoulos D. Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy. J Inherit Metab Dis. [Research Support, Non-U.S. Gov\u2019t]. 2018 11;41(6):1205-14.","DOI":"10.1007\/s10545-018-0166-3"},{"issue":"1","key":"3981_CR56","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.nmd.2019.11.007","volume":"01","author":"HA van Kooten","year":"2020","unstructured":"van Kooten HA, van der Harlaar L, van Doorn PA, Brusse E. Discontinuation of enzyme replacement therapy in adults with Pompe disease: evaluating the European POmpe consortium stop criteria. Neuromuscul Disord [Evaluation Study]. 2020;01(1):59\u201366.","journal-title":"Neuromuscul Disord [Evaluation Study]"},{"key":"3981_CR57","first-page":"26","volume":"26","author":"MM Dimachkie","year":"2022","unstructured":"Dimachkie MM, Barohn RJ, Byrne B, Goker-Alpan O, Kishnani PS, Ladha S, et al. Long-term safety and efficacy of avalglucosidase Alfa in patients with Late-Onset Pompe disease. Neurology. 2022;26:26.","journal-title":"Neurology"},{"key":"3981_CR58","first-page":"06","volume":"06","author":"BJ Byrne","year":"2023","unstructured":"Byrne BJ, Schoser B, Kishnani PS, Bratkovic D, Clemens PR, Goker-Alpan O, et al. Long-term safety and efficacy of cipaglucosidase Alfa plus miglustat in individuals living with Pompe disease: an open-label phase I\/II study (ATB200-02). J Neurol. 2023;06:06.","journal-title":"J Neurol"},{"key":"3981_CR59","doi-asserted-by":"crossref","unstructured":"van der Ditters IAM, van der Brusse E, Huidekoper HH. Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study. Orphanet Journal Of Rare Diseases. [Research Support, Non-U.S. Gov\u2019t]. 2023 05 08;18(1):108.","DOI":"10.1186\/s13023-023-02715-4"},{"key":"3981_CR60","volume-title":"CHMP assessment report pombiliti","author":"European Medicines Agency","year":"2022","unstructured":"European Medicines Agency. CHMP assessment report pombiliti. Amsterdam: EMA; 2022."},{"key":"3981_CR61","volume-title":"CHMP assessment report for myozyme","author":"European Medicines Evaluation Agency","year":"2009","unstructured":"European Medicines Evaluation Agency. CHMP assessment report for myozyme. Amsterdam: EMEA; 2009."},{"key":"3981_CR62","volume-title":"Summary of product characteristics: myozyme 50 Mg powder for concentrate for solution for infusion","author":"European Medicines Evaluation Agency","year":"2011","unstructured":"European Medicines Evaluation Agency. Summary of product characteristics: Myozyme 50\u00a0mg powder for concentrate for solution for infusion. Amsterdam: EMEA; 2011."},{"key":"3981_CR63","doi-asserted-by":"crossref","unstructured":"Kishnani PS, Diaz-Manera J, Kushlaf H, Ladha S, Mozaffar T, Straub V et al. Efficacy and safety of avalglucosidase alfa in participants with late-onset Pompe disease after 145 weeks of treatment during the COMET trial. Mol Genet Metab. [Journal article; Conference proceeding]. 2023;138(2).","DOI":"10.1016\/j.ymgme.2022.107185"},{"issue":"suppl 1","key":"3981_CR64","first-page":"A17","volume":"5","author":"RD Henderson","year":"2023","unstructured":"Henderson RD, Schoser B, Kishnani PS, Kushlaf H, Ladha S, Mozaffar T, et al. EFFICACY and SAFETY of AVALGLUCOSIDASE ALFA in PARTICIPANTS with LATE-ONSET POMPE DISEASE after 145 WEEKS\u2019 TREATMENT: PHASE 3 COMET TRIAL. BMJ Neurol Open. 2023;5(suppl 1):A17.","journal-title":"BMJ Neurol Open"},{"key":"3981_CR65","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13023-024-03156-3","volume":"19","author":"KG Claeys","year":"2024","unstructured":"Claeys KG, Kushlaf H, Raza S, Hummel N, Shohet S, Keyzor I, et al. Minimal clinically important differences in six-minute walking distance in late-onset Pompe disease. Orphanet J Rare Dis. 2024;19:154.","journal-title":"Orphanet J Rare Dis"},{"key":"3981_CR66","doi-asserted-by":"publisher","first-page":"e16223","DOI":"10.1111\/ene.16223","volume":"31","author":"A Lika","year":"2024","unstructured":"Lika A, van der Andrinopoulou ER, van der Rizopoulos D, Kruijshaar ME. Establishing how much improvement in lung function and distance walked is clinically important for adult patients with Pompe disease. Eur J Neurol. 2024;31:e16223.","journal-title":"Eur J Neurol"},{"key":"3981_CR67","volume-title":"CHMP assessment report nexviadyme","author":"European Medicines Agency","year":"2021","unstructured":"European Medicines Agency. CHMP assessment report nexviadyme. Amsterdam: EMA; 2021."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03981-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03981-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03981-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T18:56:44Z","timestamp":1757444204000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03981-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3981"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03981-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"29 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}}],"article-number":"451"}}